{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:10:31Z","timestamp":1735431031607,"version":"3.32.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,28]]},"DOI":"10.7759\/cureus.76538","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T23:53:41Z","timestamp":1735430021000},"source":"Crossref","is-referenced-by-count":0,"title":["Sensitivity to Tyrosine Kinase Inhibitors in a Human Philadelphia Chromosome-Positive (Ph+) Leukemia Model With the T315I-Inclusive Compound Mutation"],"prefix":"10.7759","author":[{"given":"Thao T","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Harama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Kagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koshi","family":"Akahane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumiko","family":"Goi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Inukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62120-0","article-title":"Chronic myeloid leukaemia","volume":"385","author":"Apperley JF","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015, 385:1447-59. 10.1016\/S0140-6736(13)62120-0","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3317","article-title":"Pushing the limits of targeted therapy in chronic myeloid leukaemia","volume":"12","author":"O'Hare T","year":"2012","unstructured":"O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012, 12:513-26. 10.1038\/nrc3317","journal-title":"Nat Rev Cancer"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie MS","year":"2014","unstructured":"Zabriskie MS, Eide CA, Tantravahi SK, et al.. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014, 26:428-42. 10.1016\/j.ccr.2014.07.006","journal-title":"Cancer Cell"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-096396","article-title":"In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad JS","year":"2008","unstructured":"Khorashad JS, Milojkovic D, Mehta P, et al.. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood. 2008, 111:2378-81. 10.1182\/blood-2007-06-096396","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare T","year":"2009","unstructured":"O'Hare T, Shakespeare WC, Zhu X, et al.. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009, 16:401-12. 10.1016\/j.ccr.2009.09.028","journal-title":"Cancer Cell"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes JE","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, et al.. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012, 367:2075-88. 10.1056\/NEJMoa1205127","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.4718","article-title":"Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia","volume":"33","author":"Moslehi JJ","year":"2015","unstructured":"Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol. 2015, 33:4210-18. 10.1200\/JCO.2015.62.4718","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes JE","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, et al.. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018, 132:393-404. 10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1990","article-title":"Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development","volume":"62","author":"Hanley MJ","year":"2022","unstructured":"Hanley MJ, Diderichsen PM, Narasimhan N, Srivastava S, Gupta N, Venkatakrishnan K. Population pharmacokinetics of ponatinib in healthy adult volunteers and patients with hematologic malignancies and model-informed dose selection for pediatric development. J Clin Pharmacol. 2022, 62:555-67. 10.1002\/jcph.1990","journal-title":"J Clin Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie AA","year":"2017","unstructured":"Wylie AA, Schoepfer J, Jahnke W, et al.. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. 2017, 543:733-7. 10.1038\/nature21702","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014689","article-title":"Asciminib: a new therapeutic option in chronic-phase CML with treatment failure","volume":"139","author":"Yeung DT","year":"2022","unstructured":"Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure. Blood. 2022, 139:3474-9. 10.1182\/blood.2021014689","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.004","article-title":"Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants","volume":"36","author":"Eide CA","year":"2019","unstructured":"Eide CA, Zabriskie MS, Savage Stevens SL, et al.. Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants. Cancer Cell. 2019, 36:431-43.e5. 10.1016\/j.ccell.2019.08.004","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2008.04.018","article-title":"Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression","volume":"1","author":"Bueno MJ","year":"2008","unstructured":"Bueno MJ, de Castro IP, de Cedr\u00f3n MG, et al.. Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell. 2008, 1:496-506. 10.1016\/j.ccr.2008.04.018","journal-title":"Cancer Cell"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0482","article-title":"BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations","volume":"7","author":"Lee TS","year":"2008","unstructured":"Lee TS, Ma W, Zhang X, Giles F, Cortes J, Kantarjian H, Albitar M. BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations. Mol Cancer Ther. 2008, 7:3834-41. 10.1158\/1535-7163.MCT-08-0482","journal-title":"Mol Cancer Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007661","article-title":"Reciprocal t(9;22) ABL\/BCR fusion proteins: leukemogenic potential and effects on B cell commitment","volume":"4","author":"Zheng X","year":"2009","unstructured":"Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M. Reciprocal t(9;22) ABL\/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One. 2009, 4:e7661. 10.1371\/journal.pone.0007661","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-0774.2005.tb00054.x","article-title":"Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR\/ABL transcripts but missing normal ABL gene","volume":"18","author":"Van PN","year":"2005","unstructured":"Van PN, Xinh PT, Kano Y, Tokunaga K, Sato Y. Establishment and characterization of A novel Philadelphia-chromosome positive chronic myeloid leukemia cell line, TCC-S, expressing P210 and P190 BCR\/ABL transcripts but missing normal ABL gene. Hum Cell. 2005, 18:25-33. 10.1111\/j.1749-0774.2005.tb00054.x","journal-title":"Hum Cell"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-27767-6","article-title":"T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system","volume":"8","author":"Tamai M","year":"2018","unstructured":"Tamai M, Inukai T, Kojika S, et al.. T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR\/Cas9 system. Sci Rep. 2018, 8:9966. 10.1038\/s41598-018-27767-6","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03369-x","article-title":"Introduction of the T315I gatekeeper mutation of BCR\/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR\/Cas9 system","volume":"116","author":"Nguyen TT","year":"2022","unstructured":"Nguyen TT, Tamai M, Harama D, et al.. Introduction of the T315I gatekeeper mutation of BCR\/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR\/Cas9 system. Int J Hematol. 2022, 116:534-43. 10.1007\/s12185-022-03369-x","journal-title":"Int J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3190","article-title":"Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining","volume":"33","author":"Maruyama T","year":"2015","unstructured":"Maruyama T, Dougan SK, Truttmann MC, Bilate AM, Ingram JR, Ploegh HL. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol. 2015, 33:538-42. 10.1038\/nbt.3190","journal-title":"Nat Biotechnol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng B","year":"2005","unstructured":"Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005, 44:879-94. 10.2165\/00003088-200544090-00001","journal-title":"Clin Pharmacokinet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1312","article-title":"Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor","volume":"58","author":"Tian X","year":"2018","unstructured":"Tian X, Zhang H, Heimbach T, He H, Buchbinder A, Aghoghovbia M, Hourcade-Potelleret F. Clinical pharmacokinetic and pharmacodynamic overview of nilotinib, a selective tyrosine kinase inhibitor. J Clin Pharmacol. 2018, 58:1533-40. 10.1002\/jcph.1312","journal-title":"J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia","volume":"72","author":"Ishida Y","year":"2016","unstructured":"Ishida Y, Murai K, Yamaguchi K, et al.. Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. Eur J Clin Pharmacol. 2016, 72:185-93. 10.1007\/s00228-015-1968-y","journal-title":"Eur J Clin Pharmacol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes TP","year":"2019","unstructured":"Hughes TP, Mauro MJ, Cortes JE, et al.. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med. 2019, 381:2315-26. 10.1056\/NEJMoa1902328","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8166-3-15","article-title":"Genomic amplification of BCR\/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines","volume":"3","author":"Virgili A","year":"2010","unstructured":"Virgili A, Nacheva EP. Genomic amplification of BCR\/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines. Mol Cytogenet. 2010, 3:15. 10.1186\/1755-8166-3-15","journal-title":"Mol Cytogenet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.13.12.7587-7595.1993","article-title":"A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins","volume":"13","author":"McWhirter JR","year":"1993","unstructured":"McWhirter JR, Galasso DL, Wang JY. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins. Mol Cell Biol. 1993, 13:7587-95. 10.1128\/mcb.13.12.7587-7595.1993","journal-title":"Mol Cell Biol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1021\/bi051493t","article-title":"Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain","volume":"44","author":"Taylor CM","year":"2005","unstructured":"Taylor CM, Keating AE. Orientation and oligomerization specificity of the Bcr coiled-coil oligomerization domain. Biochemistry. 2005, 44:16246-56. 10.1021\/bi051493t","journal-title":"Biochemistry"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2005.05.004","article-title":"Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia","volume":"163","author":"Ossard-Receveur A","year":"2005","unstructured":"Ossard-Receveur A, Bernheim A, Clausse B, et al.. Duplication of the Ph-chromosome as a possible mechanism of resistance to imatinib mesylate in patients with chronic myelogenous leukemia. Cancer Genet Cytogenet. 2005, 163:189-90. 10.1016\/j.cancergencyto.2005.05.004","journal-title":"Cancer Genet Cytogenet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-553X.2007.00957.x","article-title":"Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia","volume":"30","author":"Otero L","year":"2008","unstructured":"Otero L, Ornellas MH, Dobbin J, de Souza Fernandez T. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia. Int J Lab Hematol. 2008, 30:346-8. 10.1111\/j.1751-553X.2007.00957.x","journal-title":"Int J Lab Hematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergen.2022.07.002","article-title":"Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient","volume":"266-7","author":"Davulcu EA","year":"2022","unstructured":"Davulcu EA, Pekerbas M, Karaca E, Durmaz B, \u00d6zsan N, Ak\u0131n H, Saydam G. Complex karyotype with double Philadelphia chromosome and T315I mutation results in blastic phase and extensive extramedullary infiltration in a chronic myeloid leukemia patient. Cancer Genet. 2022, 266-7:74-80. 10.1016\/j.cancergen.2022.07.002","journal-title":"Cancer Genet"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1186\/s13039-014-0089-0","article-title":"Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case","volume":"7","author":"Al-Achkar W","year":"2014","unstructured":"Al-Achkar W, Moassass F, Ikhtiar A, Liehr T, Othman MA, Wafa A. Hyperdiploidy associated with T315I mutation in BCR-ABL kinase domain in an accelerated phase-chronic myeloid leukemia case. Mol Cytogenet. 2014, 7:89. 10.1186\/s13039-014-0089-0","journal-title":"Mol Cytogenet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/327495-sensitivity-to-tyrosine-kinase-inhibitors-in-a-human-philadelphia-chromosome-positive-ph-leukemia-model-with-the-t315i-inclusive-compound-mutation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T23:53:42Z","timestamp":1735430022000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/327495-sensitivity-to-tyrosine-kinase-inhibitors-in-a-human-philadelphia-chromosome-positive-ph-leukemia-model-with-the-t315i-inclusive-compound-mutation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.76538","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,28]]}}}